Business Context and Reporting Period
Serina Therapeutics, Inc. (NYSE American: SER) is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases, primarily Parkinson's disease. The company utilizes its proprietary POZ (poly(2-oxazoline)) drug delivery technology to modify existing drugs, aiming to improve efficacy and safety profiles through long-acting subcutaneous injections. This Form 10-K covers the fiscal year ended December 31, 2025.
Key operational milestones during the period included:
- Receipt of FDA clearance for the Investigational New Drug (IND) application for lead candidate SER-252 (POZ-apomorphine) in January 2026.
- Enrollment and dosing of the first patient in the Phase 1b clinical trial for SER-252 in February 2026.
- Completion of a Phase Ia study for SER-214 (POZ-rotigotine), which served as a proof-of-principle but is not being advanced internally.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $130 | $56 |
| Net Loss | $(19,215) | $(11,207) |
| Operating Expenses | $24,152 | $17,104 |
| Cash and Cash Equivalents (Year End) | $3,056 | $3,672 |
| Accumulated Deficit | $(63,500) | $(44,318) |
| Net Cash Used in Operating Activities | $(17,955) | $(17,137) |
| Net Cash Provided by Financing Activities | $17,412 | $13,212 |
Note: The company reported no product sales revenue; total revenue consists of grant revenues.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $8.0 million (71.5%) year-over-year, driven primarily by a $5.7 million increase in Research and Development (R&D) expenses and a $1.4 million increase in General and Administrative (G&A) expenses.
- R&D Expense Growth: R&D expenses rose to $13.2 million from $7.5 million, attributed to increased clinical activities, higher headcount, consultant spend, and amortization of a prepaid technology access fee.
- Financing Activity: The company raised significant capital in 2025, including $4.9 million from a private placement of Series A Convertible Preferred Stock, $4.9 million from a convertible note drawdown, and $2.6 million from At-The-Market (ATM) offerings.
- Listing Compliance: The company received notice from NYSE American in January 2026 regarding non-compliance with stockholders' equity requirements (reported equity of ~$1.6 million vs. $4.0 million minimum) and submitted a compliance plan to regain compliance by July 2027.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has raised substantial doubt about the company's ability to continue as a going concern. As of December 31, 2025, cash on hand ($3.1 million) is insufficient to fund operations for the next twelve months. The company requires additional financing to execute its operating plan.
Outlook and Guidance
The company expects to continue incurring operating losses for the foreseeable future. Future capital requirements depend on the progress of clinical trials for SER-252 and other candidates. The company plans to fund operations through equity offerings, debt financings, ATM programs, or strategic collaborations.
Key Risks
- Regulatory Delays: The FDA placed a clinical hold on the SER-252 IND in November 2025 regarding an excipient, which was cleared in January 2026. Future regulatory approvals are uncertain.
- Capital Constraints: Failure to secure additional funding could force the company to delay, curtail, or terminate research and development programs.
- Delisting Risk: Failure to meet NYSE American listing standards could result in delisting, impacting liquidity and the ability to raise capital.
- Technology and Development Risk: Product candidates are in early stages; there is no guarantee of successful development, regulatory approval, or commercialization.
Unusual Items
The financial results include non-cash items such as a $4.3 million gain from the change in fair value of warrant liabilities and $3.8 million in stock-based compensation expense.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $16.0 million in gross proceeds received from the March 2026 private placement to extend the operating runway beyond the current 12-month deficit.
- NYSE Compliance: Monitor the company's progress in meeting the $4.0 million stockholders' equity requirement to avoid delisting from NYSE American.
- SER-252 Trial Progress: Track enrollment and dosing milestones for the Phase 1b trial of SER-252, as these trigger funding tranches under the 2025 Convertible Note (now amended) and are critical for future financing.
- Dilution Impact: Assess the dilution effects of the recent private placement, ATM sales, and outstanding warrants/options (over 7 million potential shares).
- Related Party Transactions: Review the concentration of ownership and financing provided by Juvenescence Limited (approx. 33% owner) and Board members.